乐虎国际娛乐

English
banner
Products
Home

API

LETROZOLE 112809-51-5

LETROZOLE 112809-51-5

USP 32
  • Product Details

Product Information


Product name

Letrozole

Molecular Formula

C17H11N5

Molecular Weight

285.3

CAS No.

112809-51-5

Quality Standard

USP32, medical grade

Appearance

White powder


COA of Letrozole


Items

Specification

Appearance

White to yellowish, crystalline powder

Identification

A.IR spectrum of sample should be identical to that of Reference Standard;

The retention time of major peak in the chromatogram of the Assay preparation should correspond to that in the chromatogram of Standard preparation, as obtained in the Assay.

Showing the white precipitate reaction.

Water

Not more than 0.3%

Residue on Ignition

Not more than 0.1%

Heavy Metals

Not more than 0.001%

 

Related Compounds

Compound A: Not more than 0.1%

4,4’,4”-methylidenetrisbenzonitrile: Not more than 0.2%

Any other impurity: Not more than 0.1%

All other impurities: Not more than 0.3%

Residual Sovents

Ethanol: Not more than 3000ppm

Ethyl acetate: Not more than 2000ppm

DMF: Not more than 880ppm

Microbe Limit

Bacteria: Not more than 200/g

Mold and yeast: Not more than 50/g

Escherichia coli: should be absent

Assay(anhydrous)

98.0% to 102.0% of Cl7H11N5 on dried basis

Packaging and Storage

Preserve in tight containers at controlled room temperature.

Conclusion

Conforms to the USP32.


Usage


Function of Letrozole
Letrozole is a new generation of highly selective aromatase inhibitors. It is a synthetic benztriazole derivative. By inhibiting aromatase, estrogen levels are reduced, thereby eliminating the stimulating effect of estrogen on tumor growth. The activity in the body is 150-250 times stronger than that of the first generation aromatase inhibitor amuromet. Because of its high selectivity, it does not affect glucocorticoids, mineralocorticoids, and thyroid function. Large doses have no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity, mutagenicity and carcinogenic effects on various systems and target organs in the whole body, and has less toxic and side effects, and is well tolerated. Compared with estrogen drugs, the anti-tumor effect is stronger. It is suitable for the treatment of postmenopausal patients with advanced breast cancer who are not responding to anti-estrogen therapy and early treatment of breast cancer.


In December 2005, the British drug and health product regulatory agency approved Letrozole (Fron乐虎国际娛乐) produced by Novartis of Switzerland to be used in the treatment of breast cancer patients, allowing it to be used in surgically treated, early menopausal hormone-positive mammary glands Cancer patients. This is the second aromatase inhibitor approved following the approval of AstraZeneca ’s Rainin in June 2005. Both drugs have shown in clinical trials that they can better prevent the risk of breast cancer recurrence compared to current standard tamoxifen treatment.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

MUPIROCIN
MUPIROCIN 12650-69-0
99% up / GMP
IMATINIB MESYLATE
IMATINIB MESYLATE 220127-57-1
In-house Standard
CEFTIOFUR SODIUM
CEFTIOFUR SODIUM 104010-37-9
In-house Specification
OSELTAMIVIR PHOSPHATE
OSELTAMIVIR PHOSPHATE 204255-11-8
99% up , Pharmaceutical Grade
THYMOPENTIN
THYMOPENTIN 69558-55-0
99% up Medical Grade
LOSARTAN POTASSIUM
LOSARTAN POTASSIUM 124750-99-8
98.5% up, USP32 
AZILSARTAN
AZILSARTAN 147403-03-0
99% up, JP/ GMP / PMDA / DMF
CARMUSTINE
CARMUSTINE 154-93-8
96.0% - 102.0% 
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

home

products

about

contact

乐优彩票登入,备用,官方网址 乐优彩票天天红单下载 乐优彩票网址是多少 乐优炫彩app 乐优炫彩app下载 乐博彩票官方app 乐优炫彩官网 乐优炫彩彩票app下载 乐体育app下载 乐善彩票网址